KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Operating Leases: 2019-2024

Historic Operating Leases for Pacira BioSciences (PCRX) over the last 6 years, with Dec 2024 value amounting to $44.6 million.

  • Pacira BioSciences' Operating Leases fell 14.86% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year decrease of 14.86%. This contributed to the annual value of $44.6 million for FY2024, which is 18.54% down from last year.
  • Latest data reveals that Pacira BioSciences reported Operating Leases of $44.6 million as of FY2024, which was down 18.54% from $54.8 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Operating Leases ranged from a high of $71.7 million in FY2021 and a low of $44.6 million during FY2024.
  • For the 3-year period, Pacira BioSciences' Operating Leases averaged around $54.8 million, with its median value being $54.8 million (2023).
  • In the last 5 years, Pacira BioSciences' Operating Leases skyrocketed by 73.49% in 2020 and then dropped by 18.54% in 2024.
  • Over the past 5 years, Pacira BioSciences' Operating Leases (Yearly) stood at $71.0 million in 2020, then grew by 0.99% to $71.7 million in 2021, then fell by 9.65% to $64.8 million in 2022, then decreased by 15.43% to $54.8 million in 2023, then decreased by 18.54% to $44.6 million in 2024.